Fosun Pharma (02196.HK): Controlled Subsidiary’s HLX3902 Injection Obtains Clinical Trial Approval
NewTimeSpace News: On June 17, 2026, Fosun Pharma (02196.HK) issued an announcement stating that its controlled subsidiary Shanghai Henlius Biotech, Inc. has secured approval from the National Medical Products Administration to launch a Phase I clinical trial of HLX3902 Injection for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors.
The candidate drug has previously obtained clinical trial notification clearance from the Therapeutic Goods Administration (TGA) of Australia, and its Phase I clinical trial protocol has been approved by the relevant ethics committee.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- FOSUN PHARMA (02196.HK): Registration application for new specification of HLX14 denosumab biosimilar accepted by NMPA
- FOSUN PHARMA (02196.HK): FXS5626 Approved for Phase II/III Trial in Non-Segmental Vitiligo
- FOSUN PHARMA (02196.HK): Sells 6% Stake in India's Gland Pharma for Approximate USD 294 Million
- FOSUN PHARMA (02196.HK): Licensed drug weliteitumab injection (GR1803) granted conditional approval for relapsed or refractory multiple myeloma
- FOSUN PHARMA (02196.HK): Repurchases 217,000 H shares for approximately HKD 3.587 million
